KOMPAL PARMAR: Open Payments
NPI 1710270988 · LUBBOCK, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,649 in 149 payments from 23 companies in 2025. Trend: 2023 $1,786 · 2024 $1,715 · 2025 $3,649
Food & beverage: $3,649
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 17 | $397 |
| MAYNE PHARMA COMMERCIAL LLC | 7 | $339 |
| Novo Nordisk Inc | 15 | $330 |
| GlaxoSmithKline, LLC. | 18 | $304 |
| Verona Pharma, Inc. | 13 | $259 |
| Amgen Inc. | 12 | $238 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $207 |
| Axsome Therapeutics, Inc. | 10 | $195 |
| Bayer Healthcare Pharmaceuticals Inc. | 5 | $179 |
| AstraZeneca Pharmaceuticals LP | 3 | $160 |
Products named: Ohtuvayre, Wegovy, QULIPTA, CAPLYTA, Kerendia, Auvelity, AIRSUPRA, GEMTESA.
Industry payments across TX — which companies pay providers there.
